Bcl-2 Gene Expression

Last Modified: October 18, 2006


Dear OncoLink "Ask The Experts,"

My wife, age 22, was diagnosed with stage IIIA clear cell adenocarcinoma of the cervix. Is it true that if Bcl-2 staining is found in the tumor, then that would make it more resistant to conventional treatments? Are there any approved therapies for such resistant tumors (i.e. targeting Bcl-2)?


Christina S. Chu, MD, Assistant Professor of the Division of Gynecologic Oncology at the University of Pennsylvania Health System, responds:

Bcl-2 gene expression is common in many tumor types and has been associated with chemotherapy resistance. At the University of Pennsylvania, we will soon be conducting a clinical trial that attempts to reverse the resistance caused by Bcl-2 gene expression, but no US FDA-approved therapies currently exist.

Standard treatment of locally advanced cervical cancer consists of radiation and radiation-sensitizing chemotherapy. The standard therapy for recurrent or persistent disease is platinum-based combination chemotherapy. In the setting where standard therapies have failed, clinical trials of newer agents may be available in your area.


How to Find the Cancer Resources You Need - Brown Bag Web Chat
by OncoLink Editorial Team
June 15, 2011

7 Tips for Giving Smart on #givingtuesday
by Christina Bach, MSW, LCSW, OSW-C
November 25, 2015

Related News

BCL2L1 Linked to Colorectal Cancer-Related Processes

Aug 31, 2011

But is not likely to be the driver behind 20q gain-linked adenoma-to-carcinoma progression

NPe6 May Beat Photofrin Photodynamic Therapy in Lung CA

Sep 2, 2011

Individualized approach based on Bcl-2/BCRP expression may improve PDT efficacy in lung cancers

Men with high tumor fatty acid synthase gene expression at substantial risk for lethal disease

Aug 5, 2010

Men with high tumor fatty acid synthase gene expression at substantial risk for lethal disease